Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020) Molecular profiling for precision cancer therapies. Genome Med 12(1):8. https://doi.org/10.1186/s13073-019-0703-1

Article  PubMed  PubMed Central  Google Scholar 

Wahida A, Buschhorn L, Fröhling S et al (2022) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3

Article  CAS  PubMed  Google Scholar 

Brown NA, Elenitoba-Johnson KSJ (2020) Enabling precision oncology through precision diagnostics. Annu Rev Pathol 15:97–121. https://doi.org/10.1146/annurev-pathmechdis-012418-012735

Article  CAS  PubMed  Google Scholar 

Mateo J, Steuten L, Aftimos P et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28(4):658–665. https://doi.org/10.1038/s41591-022-01717-2

Article  CAS  PubMed  Google Scholar 

Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17(3):183–196. https://doi.org/10.1038/nrd.2017.226

Article  CAS  PubMed  Google Scholar 

Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795. https://doi.org/10.1056/NEJMp1500523

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R (2020) Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 86:102019. https://doi.org/10.1016/j.ctrv.2020.102019

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Velden DL, van Herpen CML, van Laarhoven HWM et al (2017) Molecular tumor boards: current practice and future needs. Ann Oncol 28(12):3070–3075. https://doi.org/10.1093/annonc/mdx528

Article  PubMed  Google Scholar 

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037. https://doi.org/10.1056/nejm200104053441401

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/nejm200103153441101

Article  CAS  PubMed  Google Scholar 

Berger MF, Mardis ER (2018) The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 15(6):353–365. https://doi.org/10.1038/s41571-018-0002-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weinstein JN, Collisson EA, Mills GB et al (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120. https://doi.org/10.1038/ng.2764

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waarts MR, Stonestrom AJ, Park YC, Levine RL (2022) Targeting mutations in cancer. J Clin Invest 132:8. https://doi.org/10.1172/jci154943

Article  CAS  Google Scholar 

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275. Erratum in: Ann Oncol. 2019 May; 30(5):863–870

Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, Mulcahy M, Norden AD, Goldberg SL (2019) Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer. JCO Precis Oncol 3:PO.19.00274. https://doi.org/10.1200/po.19.00274

Lamarca A, Edeline J, Goyal L (2022) How I treat biliary tract cancer. ESMO Open 7(1):100378. https://doi.org/10.1016/j.esmoop.2021.100378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Looney A-M, Nawaz K, Webster RM (2020) Tumour-agnostic therapies. Nat Rev Drug Discov 19(6):383–385

Article  CAS  PubMed  Google Scholar 

Horak P, Leichsenring J, Goldschmid H et al (2022) Assigning evidence to actionability: an introduction to variant interpretation in precision cancer medicine. Genes Chromosom Cancer 61(6):303–313. https://doi.org/10.1002/gcc.22987

Article  CAS  PubMed  Google Scholar 

Li MM, Datto M, Duncavage EJ et al (2017) Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19(1):4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haslam A, Kim MS, Prasad V (2021) Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006–2020. Ann Oncol 32(7):926–932. https://doi.org/10.1016/j.annonc.2021.04.003

Article  CAS  PubMed  Google Scholar 

Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491–1505. https://doi.org/10.1016/j.annonc.2020.07.014

Article  CAS  PubMed  Google Scholar 

Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M (2020) When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 25:100487. https://doi.org/10.1016/j.eclinm.2020.100487

Subbiah V, Kurzrock R (2023) Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J Clin Oncol 41(17):3100–3103. https://doi.org/10.1200/jco.22.02833

Article  CAS  PubMed  Google Scholar 

Sorscher S. Do all patients diagnosed with cancer deserve germline testing? J Clin Oncol 41(24):4057–4058. https://doi.org/10.1200/jco.23.00710

Colomer R, Miranda J, Romero-Laorden N, Hornedo J, González-Cortijo L, Mouron S, Bueno MJ, Mondéjar R, Quintela-Fandino M (2023) Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement. eClinicalMedicine 60:102029. https://doi.org/10.1016/j.eclinm.2023.102029

Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586–595. https://doi.org/10.1158/2159-8290.Cd-16-1396

Article  CAS  PubMed  Google Scholar 

Sicklick JK, Kato S, Okamura R et al (2019) Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25(5):744–750. https://doi.org/10.1038/s41591-019-0407-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25(5):738–743. https://doi.org/10.1038/s41591-019-0380-z

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Stephenson JJ, Rosen P et al (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28(33):4877–4883. https://doi.org/10.1200/jco.2009.26.5983

Article  Google Scholar 

Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795. https://doi.org/10.1158/2159-8290.Cd-21-0126

Article  CAS  PubMed  Google Scholar 

Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N (2019) Defining, identifying, and understanding “exceptional responders” in oncology using the tools of precision medicine. Cancer J 25:4

Article  Google Scholar 

Wahida A, Buschhorn L, Fröhling S et al (2023) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3

Article  CAS  PubMed  Google Scholar 

Rosenquist R, Cuppen E, Buettner R et al (2022) Clinical utility of whole-genome sequencing in precision oncology. Semin Cancer Biol 84:32–39. https://doi.org/10.1016/j.semcancer.2021.06.018

Article  CAS  PubMed  Google Scholar 

Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-16-1396

Article  PubMed  Google Scholar 

Adalsteinsson VA, Ha G, Freeman SS et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1324. https://doi.org/10.1038/s41467-017-00965-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riedl JM, Hasenleithner SO, Pregartner G et al (2021) Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Ther Adv Med Oncol 13:1758835920987658. https://doi.org/10.1177/1758835920987658

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25(5):738–743. https://doi.org/10.1038/s41591-019-0380-z

Article